Note 11 - Commitments and Contingencies	9 Months Ended
Sep. 30, 2018
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	NOTE 11: COMMITMENTS AND CONTINGENCIES Lease Commitments On November 1, 2018, the Company entered into an operating lease to pay $3,660 monthly rent for a term of 22 months. The total future minimum lease payments due under this lease are $80,500. Litigation and Contingencies On October 10, 2013, a putative securities class action complaint, captioned Cook v. Atossa Genetics, Inc., et al. , No. 2:13 -cv- 01836 -RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our November 2012 initial public offering. The complaint alleged that all defendants violated Sections 11 and 12 (a)( 2 ), and that we and certain of our directors and officers violated Section 15, of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections 10 (b) and 20A of the Exchange Act and SEC Rule 10b - 5 promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between November 8, 2012 and October 4, 2013, inclusive, damages of an unspecific amount. On March 23, 2018, the parties filed a stipulation of settlement with the court to settle the matter for $3.5 million, completely funded by defendants’ insurers, and on July 20, 2018 the Court approved the settlement. This case is considered closed as of September 30, 2018. We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should not have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.

NOTE

11:

COMMITMENTS AND CONTINGENCIES

Lease Commitments

November 1, 2018,

the Company entered into an operating lease to pay

$3,660

monthly rent for a term of

months. The total future minimum lease payments due under this lease are

$80,500.

Litigation and Contingencies

October 10, 2013,

a putative securities class action complaint, captioned

Cook v. Atossa Genetics, Inc., et al.

No.

2:13

-cv-

01836

-RSM, was filed in the United States District Court for the Western District of Washington against us, certain of our directors and officers and the underwriters of our

November 2012

initial public offering. The complaint alleged that all defendants violated Sections

and

(a)(

), and that we and certain of our directors and officers violated Section

15,

of the Securities Act by making material false and misleading statements and omissions in the offering’s registration statement, and that we and certain of our directors and officers violated Sections

(b) and

20A

of the Exchange Act and SEC Rule

10b

promulgated thereunder by making false and misleading statements and omissions in the registration statement and in certain of our subsequent press releases and SEC filings with respect to our NAF specimen collection process, our ForeCYTE Breast Health Test and our MASCT device. The complaint sought, on behalf of persons who purchased our common stock between

November 8, 2012

and

October 4, 2013,

inclusive, damages of an unspecific amount.

March 23, 2018,

the parties filed a stipulation of settlement with the court to settle the matter for

$3.5

million, completely funded by defendants’ insurers, and on

July 20, 2018

the Court approved the settlement. This case is considered closed as of

September 30, 2018.

We are subject to other legal proceedings and claims that arise in the normal course of business. We believe these matters are either without merit or of a kind that should

not

have a material effect, individually or in the aggregate, on our financial position, results of operations or cash flows.